Press Releases

Havn Life Sciences announces $5 million Bought Deal Financing

Havn Life Sciences announces $5 million Bought Deal Financing

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”) is pleased to announce that it has entered into an agreement with Eight Capital, pursuant to which Eight Capital has agreed to buy, …

Havn Life Sciences announces $5 million Bought Deal Financing Read More »

Havn Life Sciences undertakes one of the first preclinical studies on psilocybin and the immune system

This is one of the first studies to examine how psilocybin affects the immune system and is a required step to file an application with the Food and Drug Administration (FDA), for a Phase 1 clinical study in humans. Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or …

Havn Life Sciences undertakes one of the first preclinical studies on psilocybin and the immune system Read More »

Havn Life Psychedelics Heroic Hearts

Havn Life Sciences to supply psychedelic compounds to clinical studies focused on veterans and PTSD

Havn Life will collaborate on future clinical studies in the U.S. and Canada with Heroic Hearts to investigate effects of low-dosage psychoactive compounds on veterans the post-traumatic stress disorder (PTSD). Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”), a Canadian biotechnology company pursuing standardized extraction …

Havn Life Sciences to supply psychedelic compounds to clinical studies focused on veterans and PTSD Read More »

Havn Life Sciences announces Investor Relations Marketing Campaigns

Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”), is pleased to announce that it has entered into investor relations agreements with Media Relations Publishing (“MRP”) and Midam Ventures, LLC (“Midam”), respectively, pursuant to which, in exchange for payment by the Company of CAD$500,000 to each …

Havn Life Sciences announces Investor Relations Marketing Campaigns Read More »

Westwood Institute Havn Life partnership annoucement

Havn Life Sciences partners with veterans mental health non-profit, Westwood Institute

Westwood Institute founder, Dr. Marvin Westwood will work with Havn Life’s research team to develop best practices for combining therapy and psychedelic interventions for veterans. Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research and …

Havn Life Sciences partners with veterans mental health non-profit, Westwood Institute Read More »

David King CDPRG Havn Life

Havn Life attracts international drug science and policy expert, joins UK policy reform group

Havn Life has joined the UK-based Conservative Drug Policy Reform Group (CDPRG), a group organized to benefit drug policy-making The Havn Life Advisory Board adds Mr. King, a vocal advocate for drug policy reform and research. Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”),  a …

Havn Life attracts international drug science and policy expert, joins UK policy reform group Read More »

Havn Life Sciences announces $5.46 million warrant exercise

Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”) is pleased to announce that 10,927,856 common share purchase warrants (“Warrants”) have been exercised (“Exercise”), resulting in proceeds to the Company of $5.46 million. The Warrants had originally been issued by the Company pursuant to a private …

Havn Life Sciences announces $5.46 million warrant exercise Read More »

Havn Life announces Voluntary Escrow of 6,300,000 Shares

The Voluntary Escrow further validates investors belief and support of Havn Life’s business plan and future growth strategy. Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”), is pleased to announce that certain shareholders have entered into voluntary escrow agreements with the Company pursuant to which an …

Havn Life announces Voluntary Escrow of 6,300,000 Shares Read More »

Havn Life announces launch of a range of Natural Health Products

The 7 initial formulations are designed to support and enhance memory and brain function, the immune system, energy levels, and overall wellness, while reducing the negative impacts of stress. Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”),  a biotechnology company focused on unlocking human potential …

Havn Life announces launch of a range of Natural Health Products Read More »

Havn Life Sciences to support the first modern psilocybin depression study in Germany with MIND Foundation

The research will be led by Prof. Dr. Gerhard Gründer, the only confirmed scientist developing a study to work with psychedelics in Germany since the 1970s. Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”),   a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized …

Havn Life Sciences to support the first modern psilocybin depression study in Germany with MIND Foundation Read More »

Scroll to Top